RE: Gus08 Sep 2025 12:19
I don't really want to wade in but I just want to add my own thoughts on consolidation, based on recent experience. Quite justifiably, I have very strong feelings about this.
My other share, Sareum, a junior pharmaceutical company undertook a 50:1 consolidation in early 2022. The rationale was as following (quoted directly from their RNS, dated 4th February 2022):
"The Board is of the opinion that the high number of Existing Ordinary Shares (currently 3,403,470,791) and the low absolute share price, negatively affects investors' perception of the Company and considers the Consolidation to be in the best interests of the Company and its shareholders."
The company has progressed significantly since then, even completing a phase 1 clinical trial successfully, yet the market cap has fallen over 80% from where it was at the time of consolidation. The "high" share price only served to give more "room" to fall.
With all due respect, institutions couldn't give a rats ar** about the share price, as long as the company is making progress. The market cap is the ONLY thing that counts if they want to buy them out.
The only winner with consolidation, was, remains and always will be the financial advisors and brokers who facilitate such a move. There are zero benefits to Oriole now or in the future in undertaking a consolidation.
Hopefully we can move on from discussing what is, evidently, a completely pointless endeavour.